Previous 10 | Next 10 |
home / stock / orxoy / orxoy news
Orexo successfully issues senior secured callable floating rate social bonds of SEK 500 m and announces results of the tender offer for its existing bonds PR Newswire UPPSALA, Sweden , March 13, 2024 /PRNewswire/ -- Orexo AB (publ), (" Orexo " or the " ...
Orexo strengthens its sustainability work by establishing a social financing framework PR Newswire UPPSALA, Sweden , March 8, 2024 /PRNewswire/ -- Orexo AB (publ), ('Orexo' or the 'Company') (STO: ORX) (OTCQX: ORXOY) today announces that the Company has...
Orexo contemplates issuance of senior secured callable floating rate social bonds and announces a conditional tender offer for its existing bonds PR Newswire UPPSALA, Sweden , March 8, 2024 /PRNewswire/ -- Orexo AB (publ), (" Orexo " or the " Company ...
Orexo and Sobi agree to advance feasibility study with AmorphOX PR Newswire Orexo and Sobi advance collaboration after successful exploratory feasibility study with the company´s world-class drug delivery platform, AmorphOX® The feasibility study confirmed that t...
2024-02-08 06:30:09 ET More on Orexo AB Historical earnings data for Orexo AB Financial information for Orexo AB Read the full article on Seeking Alpha For further details see: Orexo AB GAAP EPS of -SEK0.54, revenue of SEK166M
Orexo Interim Report Q4 2023, incl. Full Year Report PR Newswire UPPSALA, Sweden , Feb. 8, 2024 /PRNewswire/ -- Positive EBITDA in H2 setting the target for FY 2024 Q4 2023 highlights Total net revenues of SEK 166.0 m (156.1) EBITDA...
Orexo's OX640 development results to be presented at the 2024 AAAAI Annual Meeting in Washington, DC PR Newswire OX640 is Orexo's nasal epinephrine powder product for the acute treatment of severe allergic reactions including anaphylaxis, based on the company´s propriet...
Orexo announces FDA acceptance of New Drug Application filing for OX124, a high-dose rescue medication for opioid overdose PR Newswire OX124 is based on Orexo´s world-class drug delivery platform, amorphOX®, and is designed to reverse the effects of the most powerf...
2023-11-02 10:37:31 ET More on Orexo AB Historical earnings data for Orexo AB Financial information for Orexo AB For further details see: Orexo AB reports Q3 interim results
Orexo Q3 2023 Interim Report PR Newswire Big step forward in launching OX124 in the US UPPSALA, Sweden , Nov. 2, 2023 /PRNewswire/ -- Q3 2023 highlights › Total net revenues of SEK 156.1 m (161.0) › ...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum held June 20 th are now available for online viewing. REGISTER NOW AT : ...
NEW YORK, June 18, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Virtual Investor Forum to be held on June 20 th , 2024. This event is co-sponsored by Zack’s Small Cap Research. ...
Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm PR Newswire UPPSALA, Sweden , May 10, 2024 /PRNewswire/ -- On March 28, 2024 , Orexo AB (publ), ("Orexo" or the " Company ") (STO: ORX) (OTCQX: ORXOY) succ...